SOLICITATION NOTICE
65 -- Whole-genome/exome/transcriptome sequencing of metastatic tumors using the Illumina NextSeq 500 high-throughput desktop sequencer
- Notice Date
- 8/12/2014
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 1050, Frederick, Maryland, 21702, United States
- ZIP Code
- 21702
- Solicitation Number
- N02RC42591-62
- Point of Contact
- Tiffany D. Kittrell, Phone: 2402765434
- E-Mail Address
-
Tiffany.kittrell@nih.gov
(Tiffany.kittrell@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Title: Whole-genome/exome/transcriptome sequencing of metastatic tumors using the Illumina NextSeq 500 high-throughput desktop sequencer Document Type: Pre-solicitation notice Solicitation Number: N02RC42591-62 Proposed Posted Date: August 12, 2014 Proposed Response Date: August 19, 2014 11:00AM EST Classification Code: 6515 NAICS Code: 334516 Small Business Size Standard: 500 Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room1E144, Bethesda, MD 20892 USA Description: The National Cancer Institute (NCI), Center for Cancer Research plans to procure on a sole source basis from Illumina Inc. at 5200 Illumina Way San Diego, CA 92122 for an Illumina NextSeqTM 500 Sequencing V System. This acquisition will be processed under FAR Part 12 – Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.106-1 (b) (2) and FAR 13.501 (a)(1)(ii).The North American Industry Classification System Code is 334516 and the business size standard in 500. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined that there is no opportunity to acquire green products or services under this procurement. Delivery shall be made within 4 weeks of contract award. The acquisition of a NextSeq high-throughput sequencer would greatly facilitate the NCI’s efforts to develop novel immune therapies for the treatment of patients with a variety of malignancies that include melanoma, kidney, lung, and bladder cancer. NCI has been using commercial sources to obtain whole exome sequence data, as we do not have access to a high throughput sequencer capable of generating this data in a timely manner. The acquisition of the NextSeq instrument, which can run between 1 to 10 samples in ~30 hours, would allow us to carry out exomic analysis of tumor samples in approximately one week’s time, which is critical in obtaining data for patients with metastatic cancer, many of whom will not be able to receive treatment on protocols targeting tumor-specific mutations unless data can be generated in a timely manner. The purpose of this acquisition is to obtain an Illumina NextSeq 500 high-throughput DNA sequencer to acquire whole genome, whole exome and whole transcriptome data that is essential for carrying out ongoing high priority projects to identify mutated antigens recognized by patient tumor-reactive T cells. Identification of these targets provides us with powerful tools that were recently used to guide cancer immunotherapy for a patient with a gastrointestinal tumor. The utilization of NGS genomic and proteomic studies we will apply to the treatment of a large population of patients with a variety of malignancies. Salient Characteristics: • Scalability from 20–120 Gb in a single run to support a broad range of applications and study sizes • The ability to perform runs, including onboard cluster generation, in 12–30 hours • Must have fully automated onboard cluster generation to enable prepped libraries to be loaded directly onto the instrument • Must have SBS chemistry with single-base extension enables accurate sequencing of homopolymers • Must have fully automated paired-end sequencing The Illumina Next Seq 500 high throughput DNA sequencer is an instrument for acquiring whole genome, whole exome and whole transciptome data that allows for carrying out ongoing high priority projects to identify mutated antigens recognized by patient tumor-reactive T cells. I identification of these targets provides NCI with powerful tools that were recently used to guide cancer immunotherapy for a patient with a gastrointestinal tumor. The utilization of NGS genomic and proteomic studies will apply to the treatment of a large population of patients with a variety of malignancies. Illumina Inc. is the only known manufacturer of a NextSeqTM 500 Sequencing system with all of the above salient characteristics. This is not a solicitation for competitive quotations. However, if any interested party, especially a small business, believes they can meet the above requirement, they may submit a statement of capabilities and or quote. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 19, 2014. Electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed to (240) -276-5401 or emailed to Tiffany Kittrell, Contract Specialist, at Tiffany.kittrell@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the System for Award Management (SAM) www.sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC42591-62 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF/N02RC42591-62/listing.html)
- Record
- SN03462512-W 20140814/140813022903-722dd96b25f9cd8a0c1b75129982ece1 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |